Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 12, 2017

Primary Completion Date

May 11, 2021

Study Completion Date

May 11, 2021

Conditions
MacTel (Macular Telangiectasia) Type 2
Interventions
BIOLOGICAL

Ciliary neurotrophic factor (CNTF)

The investigational product is the NT-501 encapsulated cell system, which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that secrete recombinant human CNTF, which were derived from genetically modified NTC-200 cells.

PROCEDURE

Surgery

Surgery to implant device for NT-501

PROCEDURE

Surgery

Sham surgery

Trial Locations (11)

2000

Sydney Eye Hospital, Sydney

3002

Centre for Eye Research Australia, East Melbourne

6009

Lions Eye Institute, Nedlands

20892

NIH Clinical Center, Rockville

30322

Emory University School of Medicine, Dept of Ophthalmology, Emory University Eye Center, Atlanta

33136

University of Miami-Miller School of Medicine, Bascom Palmer Eye Institute, Miami

44122

Retina Associates of Cleveland, Inc, Cleveland

48105

University of Michigan, Kellogg Eye Center, Ann Arbor

53705

University of Wisconsin-Madison, Department of Ophthalmology and Visual Sciences, Madison

90095

Stein Eye Institute / David Geffen School of Medicine, Los Angeles

02114

Massachusetts Eye and Ear Infirmary, Boston

Sponsors
All Listed Sponsors
lead

Neurotech Pharmaceuticals

INDUSTRY